FDA approves Amodip for feline hypertension

Amodip has entered the U.S. market with a notable regulatory first: on April 29, 2026, the FDA approved the chewable amlodipine besylate tablet for the control of systemic hypertension in cats. The approval gives veterinarians the first FDA-approved amlodipine product developed specifically for veterinary use, and it addresses a long-standing clinical reality that many feline hypertension cases have been managed with human formulations instead. (fda.gov)

That matters because feline hypertension is rarely a niche problem in practice. Consensus guidance and referral-center education have for years positioned amlodipine as the treatment of choice for most hypertensive cats, particularly those with chronic kidney disease, hyperthyroidism, or idiopathic disease. The challenge hasn’t been whether amlodipine works, but how consistently clinics can diagnose hypertension early, monitor response, and keep cats on treatment over time. Untreated disease can injure the eyes, kidneys, heart, brain, and central nervous system, and vision loss may be irreversible if intervention comes too late. (pmc.ncbi.nlm.nih.gov)

FDA said Amodip should be given once daily at a standard dose for the first 14 days, with escalation guided by the label if clinical response is inadequate. According to the Freedom of Information summary, the labeled starting range is 0.125 to 0.25 mg/kg daily, increasing if needed to 0.25 to 0.5 mg/kg, with half-tablet and whole-tablet dosing based on body weight. Cats weighing less than 2.5 kg can’t be accurately dosed with the product. The agency also said veterinarians should monitor blood pressure regularly and check bloodwork early in treatment for possible kidney and liver value changes. (fda.gov)

The evidence package adds a little more texture than the headline approval notice. In the pivotal masked, controlled field study summarized by FDA, 64.1% of treated cats met the study’s treatment-success endpoint at day 28. The FOI summary also described common adverse reactions observed across studies, including vomiting, anorexia or inappetence, dehydration, and lethargy, with 11 cats discontinuing treatment because of adverse reactions in the effectiveness study. In a separate safety study in healthy cats dosed for six months, gingival hyperplasia emerged in a dose- and time-dependent fashion, beginning around weeks 10 to 12. (animaldrugsatfda.fda.gov)

There’s also a longer clinical story behind the brand. Amodip has been licensed in other markets for years, and published literature cited by FDA described improvement in hypertensive ocular lesions in treated cats, including retinal changes linked to target-organ damage. But the same summary noted an important limitation familiar to internists and ophthalmologists: cats that started treatment with severe fundic lesions and markedly reduced or absent vision were less likely to regain visual function, even when retinal reattachment and hemorrhage resolution occurred later. (animaldrugsatfda.fda.gov)

Industry messaging around the launch has focused on awareness as much as treatment. In an April 28, 2026, Ceva press release tied to World Hypertension Day and Feline Hypertension Awareness Month, Dr. Sarah Endersby said many cats appear healthy until disease is advanced and that a simple blood pressure check can change outcomes. Ceva also highlighted low public awareness and encouraged routine screening, especially in older cats and those with chronic kidney disease, behavior changes, or vision changes. That’s promotional context, but it aligns with long-standing guideline recommendations to screen older and at-risk cats more consistently. (ceva.com)

Why it matters: For veterinary professionals, the approval is less about changing first-line pharmacology than about reducing friction in real-world care. A feline-labeled, chewable amlodipine may improve acceptance, simplify conversations with pet parents, and support more standardized dosing and monitoring protocols in general practice. It could be especially useful in CKD-heavy feline caseloads, where hypertension is common, chronic management is the norm, and balancing blood pressure control with renal monitoring is part of routine medicine. At the same time, the label reinforces that this isn’t a set-it-and-forget-it therapy: accurate blood pressure measurement, rechecks after initiation, and early laboratory follow-up remain central to safe use. (fda.gov)

What to watch: The next signals will be commercial availability, pricing relative to generic human amlodipine, and whether the launch nudges more practices to formalize feline blood pressure screening for senior cats and cats with CKD or hyperthyroidism. If it does, the biggest impact of Amodip may be earlier detection and more reliable long-term management, not just a new box on the pharmacy shelf. (fda.gov)